Download PDF
Thromb Haemost 1998; 80(01): 140-147
DOI: 10.1055/s-0037-1615153
Rapid Communication
Schattauer GmbH

Native Atherosclerosis and Vein Graft Arterialization: Association with Increased Urokinase Receptor Expression In Vitro and In Vivo

S. Steve Okada
1   Georgetown University, Washington, DC
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
Michael A. Golden
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
P. N. Raghunath
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
John E. Tomaszewski
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
Mary L. David
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
Alice Kuo
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
Katalin Kariko
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
,
Elliot S. Barnathan
2   Departments of Medicine, Surgery, Neurosurgery, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
3   Centocor, Inc. Malvern, USA
› Author Affiliations
Further Information

Publication History

Received 11 December 1997

Accepted after revision 31 May 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Interaction of proteases with cell surface receptors may modulate cell adhesion, migration, invasion, and matrix degradation. Since the plasminogen activator system has been hypothesized to play a role in intimal thickening after various types of vascular injury, we first studied the expression of urokinase receptor (u-PAR) protein and mRNA by smooth muscle cells (SMC) grown in explant cultures from normal and diseased vessels. Using equilibrium binding studies with radiolabeled 125I-labeled single chain urokinase-type plasminogen activator (scu-PA), we determined that SMC cultured from atherosclerotic arteries expressed a higher maximal number of binding sites/cell (3.6 ± 0.4 × 105 sites/cell vs. 2.1 ± 0.3 × 105, ± SEM, p <0.05) with a similar affinity (Kd = 1.5 ± 0.1 vs. 1.2 ± 0.2 nM, p = ns). However, SMC subcultured from diseased saphenous vein grafts expressed the highest levels of u-PAR compared to SMC from normal saphenous vein (4.8 ± 0.6 × 105 sites/cell vs. 1.6 ± 0.9 × 105, ± SEM, p <0.05). Using binding studies and Northern analysis, we demonstrated a dose and time dependent upregulation of u-PAR protein and mRNA expression respectively in human SMC in response to serum stimulation. Using a rabbit specific u-PAR cDNA probe, we demonstrated a similar upregulation of u-PAR mRNA both in rabbit aortic SMC in culture in response to serum stimulation and up to a 20 fold increase in u-PAR mRNA in rabbit jugular veins in response to implantation as arterial grafts in vivo. Finally, to confirm that u-PAR mRNA is upregulated in human vessels after injury, we performed immunohistochemistry and in situ hybridization studies on coronary arteries, normal saphenous veins and saphenous veins from 10 weeks to 13 years after implantation as grafts. u-PAR mRNA was found mainly in the periadventitial microcirculation in normal veins, but was found to be upregulated in the neointima and media of thickened veins in both macrophages and smooth muscle cells. SMC near the internal elastic laminae in diseased coronary arteries appeared to express increased u-PAR mRNA. These data suggest that this increased expression of u-PAR may contribute to early lesion development.

 

  • References

  • 1 Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
    CrossrefPubMedGoogle Scholar
  • 2 Okada SS, Tomaszewski JE, Barnathan ES. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro . Exp Cell Res 1995; 217: 180-7.
    CrossrefPubMedGoogle Scholar
  • 3 Noda-Heiny H, Daugherty A, Sobel BE. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol 1995; 15: 37-43.
    CrossrefPubMedGoogle Scholar
  • 4 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380-7.
    CrossrefPubMedGoogle Scholar
  • 5 Sitrin RG, Todd III RF, Petty HR, Brock TG, Shollenberger SB, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97: 1942-51.
    CrossrefPubMedGoogle Scholar
  • 6 Okada SS, Grobmyer SR, Barnathan ES. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein in smooth muscle cell migration and invasion. Arteroscler Thromb Vasc Biol 1996; 16: 1269-76.
    CrossrefPubMedGoogle Scholar
  • 7 Grobmyer SR, Kuo A, Orishimo M, Okada S, Cines DB, Barnathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993; 268: 13291-300.
    PubMedGoogle Scholar
  • 8 Herrmann HC, Okada S, Hozakowska E, LeVeen RF, Golden M, Tomaszewski JE, Weisz PB, Barnathan ES. Inhibition of smooth muscle cell proliferation and experimental angioplasty restenosis by β-cyclodextrin tetradecasulfate. Arterioscler Thromb 1993; 13: 924-31.
    CrossrefPubMedGoogle Scholar
  • 9 Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB. Interaction of single chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990; 265: 2865-72.
    PubMedGoogle Scholar
  • 10 Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 1993; 53: 3109-17.
    PubMedGoogle Scholar
  • 11 Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987; 5: 126-36.
    CrossrefPubMedGoogle Scholar
  • 12 Unger ER, Brigati DJ, Chenggis ML. Automation of in situ hybridization: Application of the capillary action robotic workstation. J Histotechnol 1988; 11: 253-8.
    CrossrefPubMedGoogle Scholar
  • 13 Montone KT, Brigati DJ, Budgeon LR. Anatomic viral diagnosis is automated: The application of a robotic molecular pathology system for detection of DNA viruses in anatomic pathology substrates using immunocytochemical and nucleic acid hybridization. Yale J Biol Med 1989; 62: 141-58.
    PubMedGoogle Scholar
  • 14 Reuning U, Bang NU. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. Arterioscler Thromb 1992; 12: 1161-70.
    CrossrefPubMedGoogle Scholar
  • 15 Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-39.
    CrossrefPubMedGoogle Scholar
  • 16 Carmeliet P, Bouché A, De Clercq C, Janssens S, Pollefeyt S, Wyns S, Mulligan RC, Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Annals NY Acad Sci 1995; 748: 367-81.
    PubMedGoogle Scholar
  • 17 Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circ 1997; 96: 3180-91.
    CrossrefPubMedGoogle Scholar
  • 18 Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-8.
    CrossrefPubMedGoogle Scholar
  • 19 Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
    CrossrefPubMedGoogle Scholar
  • 20 Raghunath PN, Tomaszewski JT, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-43.
    CrossrefPubMedGoogle Scholar
  • 21 Shetty S, Kumar A, Johnson AR, Pueblitz S, Holiday D, Raghu G, Idell S. Differential expression of urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am J Respir Cell Mol Biol 1996; 15: 78-87.
    CrossrefPubMedGoogle Scholar
  • 22 Seghezzi S, Marelli R, Mandriota SJ, Nolli ML, Mazzieri R, Mignatti P. Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. J Cell Physiol 1996; 169: 300-8.
    CrossrefPubMedGoogle Scholar
  • 23 More RS, Underwood MJ, Brack MJ, de Bono DP, Gershlick AH. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc Res 1995; 29: 22-6.
    CrossrefPubMedGoogle Scholar
  • 24 Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996; 78: 405-14.
    CrossrefPubMedGoogle Scholar
  • 25 Lu H, Mabilat C, Yeh P, Guitton J-D, Li H, Pouchelet M, Shoevaert D, Legrand Y, Soria J, Soria C. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996; 380: 21-4.
    CrossrefPubMedGoogle Scholar
  • 26 Myohanen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Hoyer Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 1993; 41: 1291-1301.
    CrossrefPubMedGoogle Scholar
  • 27 Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-50.
    PubMedGoogle Scholar
  • 28 Wei Y, Lukashev M, Simon D I, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5.
    CrossrefPubMedGoogle Scholar
  • 29 Kjøller L, Kanse SM, Kirkegaard T, Rodenburg KW, Rønne E, Goodman SL, Preissner KT, Ossowki L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
    CrossrefPubMedGoogle Scholar
  • 30 Chang A, Kuo A, Barnathan ES, Okada SS. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler Thromb Vasc Biol. 1998 (In press).
    PubMedGoogle Scholar
  • 31 Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-71.
    PubMedGoogle Scholar
  • 32 Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller B M, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem 1996; 271: 29393-9.
    CrossrefPubMedGoogle Scholar